A#2650 MRI can show extent of vessel wall inflamm to guide severity of GCA Brain & orbital MRI performed Assessed 7 arteries bilaterally -> CAMRIS-GCA MRI score (0-10) 33 GCA (17 ocular), 41 not GCA CAMRIS-GCA ass w/ ocular GCA, higher severity. Improved w Rx @RheumNow #ACR24 https://t.co/19XCuZJXqF

Among axSpA patients enrolled in the BE MOBILE 1&2, those who received Bimekizumab achieved ASAS40 response earlier vs PBO Improvements in spinal pain and physical function were significantly reported as early as wk 1 in those who received BKZ vs PBO @RheumNow #ACR24 abs2363 https://t.co/JmcQdURTY4

A re-evaluation of lupus arthritis. Old dogma is RA is erosive and SLE non-erosive. With better imaging, lupus arthritis can be erosive. Vivianne Malstrom. @RheumNow #ACR24 https://t.co/JEqVPLGNfu

Did you know? #Lupus arthritis have clinical and US classifications. On MRI, findings will show: - periarticular hyperplastic tissue - capsular swelling - edematous tenosynovitis @RheumNow #ACR24 @rheumarhyme @theactiverheum https://t.co/EoKh2Q3V9Z

McInnes et al. 24 week phase 2 ARGO trial. Sonelokimab, IL-17A- and IL-17F-inhibiting nanobody, in PsA. ACR50 responses shown in picture. Good efficacy across domains, but this is phase 2, will await the phase 3. @RheumNow #ACR24 Abstr#2582 https://t.co/FQflZMPes0 https://t.co/DATqo37yib

A#2582 McInnes Sonelokimab - IL17A,F nanobody Prior P2 in PsO, HS ARGO: P2 W24 RCT Significant improv in ACR response High PASI90/100 data Up to 60% achieved MDA by W24 Improved PsAID domains (PRO) Safety no IBD, MACE, depr. 2% oral candida IZAR-1,2 - P3 ongoing #ACR24 @RheumNow https://t.co/O4fEhTC8jK

SEC demonstrated high retention rates after 5 years in pts with PsA and r-axSpA in this real-world study. Reasons for stopping SEC: lack of efficacy pt decision lost to ffup AEs Reassuring data on SECs position in the treatment of PsA/AS. @Rheumnow #ACR24 abs2344 https://t.co/zECEsheQIi

Merrill et al. SLEek LTE. ABBV-599 (Elsubrutinib and Upadacitinib Combination) and Upadacitinib monotherapy in SLE. 104 week data. SRI-4 85.4%, 82.1%, and 61.3% in the ABBV-599 HD, UPA 30 mg, and PBO to ABBV-599 HD group @RheumNow #ACR24 Abstr#2577 https://t.co/wc6Mb13U4O https://t.co/Xu1pMhAUrG

Disseminated acanthamoeba : pt with modular painful skin lesions on his palms and scalp— initially dx’d with a cutaneous vasculitis- he got worse with immunosuppression. Imaging and histology shown #ThievesMarket #ACR24 @RheumNow https://t.co/FjJ0Sk0Kxt

A#2583 Apremilast for axial inflamm in PsA, assess by CANDEN MRI scoring MOSAIC P4 open label trial Reduction in inflammation seen in vertebral bodies & posteriolateral, not in facet joints No changes in SPARCC SIJ, spine - though low baseline SIJ inflammation @RheumNow #ACR24 https://t.co/3GKEGJbtdc

A#2584 Mease Zasocitinib TAK-279 - potent, selective TYK2i P2b, 12w PsA RCT 15/30 mg - similar response, better than PBO for ACR20/50/70, MDA, DAPSA, PASDAS 29% MDA v 13% PBO Safety no signal for MACE, cancer, serious ifn, death. Mild acne signal noted @RheumNow #ACR24 https://t.co/1eqD9R5fLe

Selective TYK2i zasocitinib, results of Phase 2 DBRCT Dose dependent improvements in various PsA outcomes; NNT~5 for DAS28 remission, NNT~20 for PASDAS Hard to compare to current agents, somewhere between JAKs (woot!) & "apremlist zone" 🫣 #ACR24 @RheumNow Abstr#2584 #ACRbest https://t.co/t0y6C618ll